Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS4131 in Systemic Lupus Erythematosus
NCT07001839Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
01
Overview
Phase 1, open-label, single-arm trial of QLS4131 in systemic lupus erythematosus (SLE), sponsored by Qilu Pharmaceutical. Primary endpoints: Incidence of Treatment Emergence Adverse Events at 24 weeks and Recommended Phase 2 Dose at 24 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
QLS4131
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07001839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07001839.